Boston Partners Has $102.84 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Boston Partners raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 457,573 shares of the medical research company’s stock after purchasing an additional 1,151 shares during the period. Boston Partners owned 0.25% of IQVIA worth $102,839,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Old North State Trust LLC lifted its position in IQVIA by 342.2% during the first quarter. Old North State Trust LLC now owns 597 shares of the medical research company’s stock worth $27,000 after acquiring an additional 462 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA in the 1st quarter valued at $36,000. Live Oak Investment Partners bought a new position in IQVIA during the 4th quarter worth $41,000. Headlands Technologies LLC lifted its holdings in shares of IQVIA by 62.3% during the first quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, MBM Wealth Consultants LLC bought a new stake in shares of IQVIA in the fourth quarter valued at about $51,000. 86.82% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock opened at $204.79 on Friday. The firm has a market capitalization of $37.37 billion, a PE ratio of 34.42, a price-to-earnings-growth ratio of 2.64 and a beta of 1.42. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 2.12. The firm’s 50 day moving average is $197.42 and its 200 day moving average is $207.10. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $241.86.

Insiders Place Their Bets

In other IQVIA news, insider Constantinos Panagos sold 27,317 shares of the stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $208.67, for a total value of $5,700,238.39. Following the completion of the transaction, the insider now directly owns 14,250 shares in the company, valued at $2,973,547.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on IQV. StockNews.com began coverage on shares of IQVIA in a research note on Friday, October 6th. They issued a “hold” rating for the company. Citigroup boosted their price target on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Evercore ISI lowered their price objective on IQVIA from $260.00 to $240.00 in a research note on Wednesday, October 11th. JPMorgan Chase & Co. cut their target price on IQVIA from $262.00 to $239.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. Finally, Barclays decreased their price target on IQVIA from $245.00 to $215.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $236.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.